Mode
Text Size
Log in / Sign up

CHG index outperforms TyG index for gestational dysglycemia risk prediction in NHANES cohortsNew blood test marker predicts pregnancy sugar risks better than old methods

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider CHG index as a potential risk marker for GDM, not a standalone screening tool.

This review and comparative study analyzed data from the NHANES 2007–2018 discovery cohort and an independent clinical validation cohort comprising 217 participants. The study evaluated the cholesterol-high-density lipoprotein-glucose (CHG) index and triglyceride-glucose (TyG) index as potential biomarkers for gestational diabetes mellitus and gestational dysglycemia. The primary outcomes included self-reported GDM history in the discovery cohort and clinically diagnosed GDM in the validation cohort.

In primary adjusted models within the NHANES discovery cohort, the CHG index showed a stronger association with self-reported GDM history than the TyG index. Discriminative performance analysis revealed that the CHG index yielded a numerically higher area under the curve (AUC) than the TyG index. When models were adjusted for continuous fasting blood glucose in NHANES, the association for the TyG index was attenuated, whereas the association for the CHG index remained significantly associated.

In the clinical validation cohort, the CHG index again demonstrated numerically higher discriminative performance than the TyG index. Supportive analyses conducted on currently pregnant NHANES participants yielded directionally similar but statistically imprecise estimates. Safety data, including adverse events and tolerability, were not reported for these indices.

Key limitations include the modest overall discriminative performance of the CHG index and statistically imprecise estimates in supportive analyses due to the limited sample size of the validation cohort. The study authors note the need for further prospective studies to validate findings. Consequently, the CHG index should be interpreted as a potential risk marker rather than a standalone clinical screening tool.

Imagine waking up with a routine blood test that tells you exactly how your body handles sugar during pregnancy. For many expectant mothers, this sounds like a dream. In reality, doctors currently rely on simple fasting glucose checks to guess who might develop gestational diabetes. This guesswork can miss important risks before they become problems for mom or baby.

But a new study offers a different path. Researchers found a way to use existing blood numbers to see deeper into insulin resistance. This means spotting trouble before it starts, rather than waiting for symptoms to appear.

The Hidden Risk in Routine Blood Work

Gestational diabetes affects millions of pregnancies every year. It happens when a woman's body cannot make enough insulin to handle the extra sugar from a growing baby. If left unchecked, high blood sugar can lead to large babies, difficult births, and long-term health issues for the child.

Doctors usually wait for standard glucose tests to flag a problem. However, these tests often happen late in pregnancy. By then, the damage might already be done. There is a need for earlier warning signs that do not require expensive new machines or rare chemicals.

A New Way to Read the Numbers

Here is the twist. Your body produces triglycerides and cholesterol along with sugar. For years, doctors looked at triglycerides alone to guess insulin resistance. They used a simple math formula called the TyG index. It worked okay, but it was like looking at only one lane of traffic to judge a whole highway.

The new research suggests looking at the whole picture. By mixing cholesterol, good cholesterol (HDL), and glucose into a new formula called the CHG index, doctors get a clearer signal. Think of it like a security system that checks the front door, back door, and windows instead of just the front door.

How the Study Was Done

Scientists looked at data from thousands of people in a national health survey. They checked who had a history of gestational diabetes and compared the two math formulas. They also tested these ideas on a separate group of 217 women with confirmed diagnoses.

The goal was simple: see which math trick worked better at predicting the disease. They wanted to know if the new combination of numbers could find the problem faster and more often than the old single-number method.

The new CHG index found the disease more often than the old TyG index. In the big group of survey participants, the new marker showed a stronger link to past diabetes history. It also had a slightly better ability to separate those at risk from those who were safe.

Even after adjusting for other blood sugar levels, the new marker held its ground. The old marker lost some of its power when scientists accounted for fasting glucose. This suggests the new marker catches something the old one misses. It sees the full story of how fats and sugars interact in the blood.

But there's a catch.

This new marker is not a magic wand. It is a tool, not a replacement for standard care.

What This Means for Your Care

This research does not mean you need a new blood test tomorrow. The formulas are simple, but the systems to run them are not yet in every clinic. However, it gives doctors a new way to think about risk. If a patient has high cholesterol and high triglycerides, the new math might say, "Look closer here."

Doctors might use this insight to decide who needs an earlier glucose test. It could help them catch cases that slip through the cracks of current screening. For patients, this means a potential future where high-risk pregnancies are identified sooner.

The study authors call for more research. They need to test this in real-time clinics with real patients, not just in past survey data. They also need to see if this works for different groups of people, not just the specific population studied.

Until then, the new CHG index remains a research tool. It shows promise, but it is not ready for the doctor's office. The science is moving forward, and one day, this simple calculation could become part of routine prenatal care. For now, it serves as a reminder that looking at the whole blood picture might save the day.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundEarly risk stratification for gestational dysglycemia is important for improving maternal and neonatal outcomes. Derived from fasting triglycerides and glucose, the triglyceride–glucose (TyG) index is widely used to approximate insulin resistance, whereas the cholesterol-high-density lipoprotein-glucose (CHG) index incorporates broader lipid metabolism. We compared the associations and discriminative performance of TyG and CHG in a national survey discovery cohort and an independent clinical validation cohort.MethodsWe analyzed a survey-weighted discovery cohort from NHANES 2007–2018, in which the primary outcome was self-reported GDM history. We further evaluated an independent validation cohort with clinically diagnosed GDM (n = 217). Associations and predictive performance were assessed using multivariable logistic regression, receiver operating characteristic (ROC) analysis, calibration analysis, and decision curve analysis (DCA). Additional analyses included adjustment for continuous fasting blood glucose in NHANES, supportive analyses restricted to currently pregnant NHANES participants from 2007–2012 using proxy-defined gestational fasting dysglycemia (fasting blood glucose ≥5.1 mmol/L), and gestational-week-adjusted sensitivity analyses in the validation cohort.ResultsIn the NHANES discovery cohort, CHG showed a stronger association with self-reported GDM history than TyG in the primary adjusted models and yielded a numerically higher AUC than TyG. After additional adjustment for continuous fasting blood glucose, the association for TyG was attenuated, whereas CHG remained significantly associated. In the clinical validation cohort, CHG also showed numerically higher discriminative performance than TyG, and the overall findings remained directionally consistent after gestational-week adjustment. Supportive analyses in currently pregnant NHANES participants showed directionally similar but statistically imprecise estimates because of the limited sample size.ConclusionBoth TyG and CHG are simple, low-cost indices associated with gestational dysglycemia/GDM. Across the discovery and validation cohorts, CHG generally showed stronger associations and numerically better discrimination than TyG; however, its overall discriminative performance remained modest and should be interpreted as that of a potential risk marker rather than a standalone clinical screening tool. Further prospective studies are needed to validate these findings.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.